Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessie Chen

Urology Flower Mound, TX Medical Doctor

NPI 1245684760 CMS profile 11306462

4370 Medical Arts Dr Ste 270, Flower Mound, TX 75028

Open in the dashboard

General payments

$5,049

96 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessie Chen of Flower Mound, TX is reported in the CMS Open Payments database as having received $5,049 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $709 30
2024 General $1,225 35
2023 General $2,832 26
2022 General $265 4
2021 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessie Chen
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Jessie Chen were reported at $709. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Jessie Chen Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $17 $358 $111–$1,000 $132
2022 $265 $476 $143–$1,263 $149
2023 $2,832 $560 $168–$1,461 $160
2024 $1,225 $563 $170–$1,464 $164
2025 $709 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Axonics Modulation Technologies, Inc. $1,612 13 payments
  2. Boston Scientific Corporation $1,033 10 payments
  3. Medtronic, Inc. $1,004 14 payments
  4. Sumitomo Pharma America, Inc. $165 8 payments
  5. Dendreon Pharmaceuticals LLC $132 4 payments
  6. Antares Pharma, Inc. $121 4 payments
  7. AbbVie, Inc. $113 5 payments
  8. Janssen Biotech, Inc. $98 4 payments
  9. Olympus America Inc. $89 4 payments
  10. Endo USA, Inc. $88 4 payments
  11. Other $593 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,877 86 payments
  2. Travel and Lodging $2,154 9 payments
  3. Gift $18 1 payment
Products named General payments · program years 2021–2025
  1. Bulkamid $1,497 8 payments
  2. Axonics $1,432 10 payments
  3. INTERSTIM $981 13 payments
  4. Solyx SIS System $945 7 payments
  5. PROVENGE $132 4 payments
  6. XYOSTED $121 4 payments
  7. ERLEADA $98 4 payments
  8. BOTOX $98 4 payments
  9. iTIND System $89 4 payments
  10. XIAFLEX $88 4 payments
  11. Other $796 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

718

Median for Urology: 1,053

Drug cost

$99,960

Median for Urology: $101,464

Branded share of claims

41.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 56 $36,763
Gemtesa Vibegron Brand 59 $35,824
Mirabegron Er Mirabegron Brand 16 $7,193
Estradiol Generic 129 $7,151
Fosfomycin Tromethamine Generic 15 $3,101
Trospium Chloride Er Trospium Chloride Brand 22 $3,067
Solifenacin Succinate Generic 47 $1,143
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 70 $982
Methenamine Hippurate Generic 15 $890
Cephalexin Generic 75 $857

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$165,318

Of which drugs: $6,493

Medicare patients

364

Average age 77

Services billed

5,029

326 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Depression 32%
Chronic kidney disease 28%
Diabetes 27%
Ischemic heart disease 24%
Osteoporosis 22%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 12 1,300 $6,492

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $80
$80 — —
XIAFLEX
  • Endo USA, Inc. $67
$67 — —
BOTOX
  • AbbVie, Inc. $58
$58 — 1,300
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $50
$50 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record